Skip to main content
Maximilian Stahl, MD, Hematology, New York, NY, Memorial Sloan-Kettering Cancer Center

MaximilianStahlMD

Hematology New York, NY

Physician

Dr. Stahl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Stahl's full profile

Already have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2018
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017
  • Hannover Medical School
    Hannover Medical SchoolClass of 2012

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2021 - 2024
  • CT State Medical License
    CT State Medical License 2017 - 2019
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • What Is the Best Method for Cytoreduction in Patients with Acute Myeloid Leukemia and Hyperleukocytosis?
    What Is the Best Method for Cytoreduction in Patients with Acute Myeloid Leukemia and Hyperleukocytosis?February 1st, 2021
  • Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)December 6th, 2016

Hospital Affiliations